Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cyclacel Pharmaceuti (NQ: CYCC )

1.880 +0.030 (+1.62%)
Streaming Delayed Price Updated: 11:43 AM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,838
Open 1.890
Bid (Size) 1.800 (1)
Ask (Size) 1.870 (2)
Prev. Close 1.850
Today's Range 1.772 - 1.950
52wk Range 0.2310 - 4.378
Shares Outstanding 1,318,257
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga

Performance

YTD
-29.06%
-29.06%
1 Month
-20.00%
-20.00%
3 Month
-9.18%
-9.18%
6 Month
+192.82%
+192.82%
1 Year
+176.46%
+176.46%

More News

Read More
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
From Cyclacel
Via GlobeNewswire
CYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q4 2023
Via InvestorPlace
Earnings Outlook For Cyclacel Pharmaceuticals
Via Benzinga
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
Earnings Scheduled For March 19, 2024
Via Benzinga
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
From Cyclacel
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
RKLB Stock Alert: The $500 Million Reason Rocket Lab Is Moving Today
Via InvestorPlace
Unity Layoffs 2024: What to Know About the Latest U Job Cuts
Via InvestorPlace
Topics Workforce
Exposures Layoff
Why Is Cyclacel Pharmaceuticals (CYCC) Stock Down 9% Today?
Via InvestorPlace
Why Juniper Networks Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
From Cyclacel
Via GlobeNewswire
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.